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Background 
 Clopidogrel is a potent antiplatelet agent (through P2Y12 
adenosine diphosphate receptor inhibition) 
 
 Treatment with clopidogrel in addition to ASA has been 
proven to reduce cardiovascular events after coronary 
stenting and following the whole spectrum of acute coronary 
syndrome (ACS): 
 
 CREDO investigators. Early and Sustained Dual Oral Antiplatelet Therapy 
Following Percutaneous Coronary Intervention. A Randomized Controlled Trial. 
JAMA. 2002;288:2411-2420. 
 
 CURE investigators. Effects of clopidogrel in addition to aspirin in patients with 
acute coronary syndromes without ST-segment elevation. NEJM 2001; 345: 
494–502. 
 
 COMMIT collaborative group. Addition of clopidogrel to aspirin in 45 852 
patients with acute myocardial infarction: randomised placebo-controlled trial. 
Lancet 2005; 366: 1607–21. 
Background 
 Clopidogrel is a prodrug converted to its metabolite by 
cytochrome P-450 isoenzymes (mainly CYP219) 
 
 Numerous drugs are known to inhibit P-450 isoenzymes, 
such as proton pump inhibitors (PPIs) 
 
 Mechanistic studies first suggested that PPIs might 
reduce the antiplatelet effect of clopidogrel, rising the 
question about the clinical significance of PPI – 
clopidogrel interaction 
Background 
 Recent published studies showed that the addition of a PPI 
to clopidogrel in ACS patients significantly increased the risk 
of recurrent cardiovascular events: 
 
 Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction 
between proton pump inhibitors and clopidogrel. CMAJ 2009; 180(7). DOI: 
10.1503/cmaj.082001 
 
 Ho MP, Maddox TM, Wang L et al. Risk of Adverse Outcomes Associated With 
Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary 
Syndrome. JAMA 2009; 301(9): 937-944. 
 
 Conflicting reports and expert opinions exist about the PPI-
clopidogrel interaction and mainly its clinical significance 
 
Aims 
 Evaluate the prescription of a PPI in addition to ASA and 
clopidogrel in ACS patients 
 
 Compare the clinical characteristics and therapeutic 
strategies of patients medicated or not with a PPI 
 
 Determine if the addition of a PPI to ASA and clopidogrel 
was associated with a worst prognosis 
Methods 
 Retrospective study - a total of 959 patients admitted with 
ACS and discharged with ASA and clopidogrel, from 
January 2004 to April 2008, were reviewed – we chose to 
analyze patients on ASA and clopidogrel as they 
represented the majority of ACS patients as well as the 
more relevant clinical scenario 
 
 Patients were classified in two groups according to the 
association or not of a PPI to ASA and clopidogrel 
 
Methods 
 All PPIs were considered except pantoprazole 
 
 Although pantoprazole can be metabolized by CYP219 
isoenzyme, it preferentially uses other routes 
 
 The prescription and clinical records were used to define 
exposure to PPI during dual antiplatelet therapy 
Results 
959 patients  
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574 not  
on PPI 
Results 
 Baseline characteristics 
65.7 ± 13.2 years 61.1 ± 13.2 years Mean ± SD p < 0.001 
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STEMI 36.7% 36.2% NS 
Killip Class > 1 24.1% 15.3% 0.002 
Mean SBP (mmHg ±SD) 138 ± 27 140 ± 27 NS 
Mean HR (bpm ±SD) 76 ± 18 75 ± 19 NS 
Results 
 Baseline characteristics 












In-hospital medical treatment 
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 Patients on PPI were older, more often had renal 
insufficiency and less often had smoking history and history 
of previous revascularization; they more often presented with 
Killip class >1 and lower haemoglobin at admission 
 
 There were no differences regarding in-hospital or discharge 
medical treatment, invasive procedure and coronary 
revascularization 
 
 Independent and positive predictors of PPI prescription were 
older age and lower haemoglobin at admission 
 
Conclusions 
 PPI prescription in addition to aspirin and clopidogrel 
was not associated with a worst prognosis in patients 
with ACS, even after adjustment for potential 
confounding factors 
Limitations 
 This was an observational and nonrandomized study, and 
as such, both identified and unidentified confounders may 
have influenced the results 
 
 Prescription and clinical records might be incomplete 
 
 Therapeutic compliance was not assessed (namely ASA, 
clopidogrel and PPI) 
 




 Randomized trials would be the preferential way to 
obtain definite conclusions about the clinical relevance 
of PPI-clopidogrel interaction 
Thank you! 
